Browsing NTNU Open by Author "Grønberg, Bjørn Henning"
Now showing items 61-71 of 71
-
Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement
Valan, Christine Damgaard; Slagsvold, Jens Erik; Halvorsen, Tarje Onsøien; Herje, Martin; Bremnes, Roy M.; Brunsvig, Paal Fr.; Brustugun, Odd Terje; Fløtten, Øystein; Levin, Nina; Sundstrøm, Stein Harald; Grønberg, Bjørn Henning (Journal article; Peer reviewed, 2018)Background/Aim: There are several definitions of limited disease (LD) in small cell lung cancer (SCLC), differing with respect to N3 disease accepted. We analyzed patients from a randomized trial comparing two schedules ... -
The relevance of tumor mutation profiling in interpretation of NGS data from cell-free DNA in non-small cell lung cancer patients
Ottestad, Anine Larsen; Wahl, Sissel Gyrid Freim; Grønberg, Bjørn Henning; Skorpen, Frank; Dai, Hong Yan (Journal article; Peer reviewed, 2019)Studies have indicated that detection of circulating tumor DNA (ctDNA) prior to treatment is a negative prognostic marker in non-small cell lung cancer (NSCLC). ctDNA is currently identified by detection of tumor mutations. ... -
Thoracic radiotherapy in limited disease small cell lung cancer
Halvorsen, Tarje Onsøien (Doctoral theses at NTNU;2017:7, Doctoral thesis, 2017)Norsk sammendrag: Lungekreft er den tredje hyppigste kreftformen, og den ledende årsaken til kreftrelaterte dødsfall. Småcellet lungekreft (SCLC) er den mest aggressive av to hovedtyper lungekreft, og forekommer nesten ... -
Thoracic Radiotherapy in Limited-Stage SCLC—a Population-Based Study of Patterns of Care in Norway From 2000 Until 2018
Graabak, Gustav; Grønberg, Bjørn Henning; Sandvei, Marie Søfteland; Nilssen, Yngvar; Halvorsen, Tarje Onsøien (Peer reviewed; Journal article, 2022)Introduction Twice-daily (BID) thoracic radiotherapy (TRT) of 45 Gy per 30 fractions is recommended for limited-stage (LS) SCLC, but most patients are treated with once-daily (OD) schedules owing to toxicity concerns ... -
Timelines in Lung Cancer Diagnostic Workup
Stokstad, Trine (Doctoral theses at NTNU;2019:241, Doctoral thesis, 2019)Lange ventetider for å starte kreftutredning eller -behandling fører til bekymring og oppfattes som en medisinsk risiko som kan påvirke mulighetene til å få effektiv behandling. Derfor er det innført krav til ventetider i ... -
Timing of severe toxicity from chemotherapy in patients with lung cancer
Sjøgren, Kristina; Jacobsen, Kristian Aalberg; Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien (Journal article; Peer reviewed, 2020)Background/Aim: The aim of this study was to investigate the timing of severe toxicity in lung cancer patients receiving chemotherapy. Patients and Methods: Patients with advanced non-small cell lung cancer or limited ... -
Trajectory of health-related quality of life during the last year of life in patients with advanced non-small–cell lung cancer
Kristensen, Are Korsnes; Grønberg, Bjørn Henning; Fløtten, Øystein; Kaasa, Stein; Solheim, Tora S (Peer reviewed; Journal article, 2022)Background The aims of this study were to assess the trajectory of health-related quality of life (HRQOL) during the last year of life in patients with advanced non-small–cell lung cancer (NSCLC) and to explore when and ... -
Treatment Outcomes of Older Participants in a Randomized Trial Comparing Two Schedules of Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC
Killingberg, Kristin Toftaker; Grønberg, Bjørn Henning; Jordhøy, Marit Slaaen; Kirkevold, Øyvind; Halvorsen, Tarje Onsøien (Peer reviewed; Journal article, 2023)Introduction Half of the patients with limited-stage SCLC (LS SCLC) are above or equal to 70 years old, but they account for less than 20% of participants in most trials. Comorbidities and reduced organ and physical ... -
Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer
Halvorsen, Tarje Onsøien; Herje, Martin; Levin, Nina; Bremnes, Roy M.; Brustugun, Odd Terje; Fløtten, Øystein; Kaasa, Stein; Sundstrøm, Stein Harald; Grønberg, Bjørn Henning (Journal article; Peer reviewed, 2016)Objectives Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small-cell lung cancer (LD SCLC). TRT should start as early as possible, often meaning with the second course due to ... -
Twice-daily thoracic radiotherapy in limited stage small-cell lung cancer
Killingberg, Kristin Toftaker (Doctoral theses at NTNU;2023:156, Doctoral thesis, 2023)Norsk sammendrag Lungekreft er den kreftformen som forårsaker flest dødsfall. Lungekreft deles inn i to hovedtyper, ikke-småcellet (NSCLC) og småcellet lungekreft (SCLC). SCLC utgjør 13-15% av tilfellene og kjennestenges ... -
Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group
Fløtten, Øystein; Grønberg, Bjørn Henning; Bremnes, Roy M.; Amundsen, Tore; Sundstrøm, Stein Harald; Rolke, Heidi; HORNSLIEN, KJERSTI; Wentzel-Larsen, Tore; Aasebø, Ulf; von Plessen, Christian (Journal article; Peer reviewed, 2012)Background: Platinum-based doublet chemotherapy is the standard first-line treatment for advanced non-small cell lung cancer (NSCLC), but earlier studies have suggested that non-platinum combinations are equally effective ...